Oklahoma Medical Research Foundation

Running trials

• Recruiting

  Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis

  NCT07878923· Oklahoma Medical Research Foundation· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Skeletal Muscle Aging and Responsiveness in Aged People With MS

  NCT07500727· Oklahoma Medical Research Foundation· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Vor Biopharma· Source

• Recruiting

  A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

  NCT06875960· Phase 4· Bristol-Myers Squibb· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Bristol-Myers Squibb· Source

• Recruiting

  Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

  NCT07225387· Phase 4· NephroNet, Inc.· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

  NCT05799378· Phase 3· NYU Langone Health· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Recruiting

  Safety of the Herpes Zoster Subunit Vaccine in Lupus

  NCT05559671· Phase 4· NYU Langone Health· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Sanofi· Source

• Recruiting

  Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  NCT05566769· Ad scientiam· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Active, not recruiting

  Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  NCT05285891· Phase 4· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

  NCT04221477· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)7 recruiting
• Multiple sclerosis2 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Terminated

  Next-Gen MS: Feed-forward PRO Data for MS Research

  NCT04907305· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  The MS-LINK™ Outcomes Study

  NCT04735406· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Phase 3· Sanofi· Source

• Completed

  Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

  NCT03963375· Phase 4· Gregory Wu· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source

• Completed

  Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

  NCT02633163· Phase 2· Medical University of South Carolina· Source

• Completed

  Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328· Johns Hopkins University· Source

• Completed

  Study of Anti-Malarials in Incomplete Lupus Erythematosus

  NCT03030118· Phase 2· Milton S. Hershey Medical Center· Source

• Recruiting

  Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

  NCT00198068· Hospital for Special Surgery, New York· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lupus (SLE)30 works · 13 trials
• Sjögren's disease4 works · 1 trial